Bafna Pharmaceuticals (NSE:BAFNAPH) E10: ₹3.99 (As of Mar. 2026)


NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
59 GF Score
Price ₹194.68
GF Value ₹90.56
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals E10?

Bafna Pharmaceuticals NSE:BAFNAPH +5.00% 59 E10 is ₹3.99 as of Mar. 2026. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 59/100 and a GF Value™ of ₹90.56 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Bafna Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was ₹1.160. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹3.99 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Bafna Pharmaceuticals's average E10 Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-26), Bafna Pharmaceuticals's current stock price is ₹194.68. Bafna Pharmaceuticals's E10 for the quarter that ended in Mar. 2026 was ₹3.99. Bafna Pharmaceuticals's Shiller PE Ratio of today is 48.79.

During the past 13 years, the highest Shiller PE Ratio of Bafna Pharmaceuticals was 45.88. The lowest was 18.22. And the median was 23.19.


Bafna Pharmaceuticals  (NSE:BAFNAPH) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Bafna Pharmaceuticals's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=194.68/3.99
=48.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Bafna Pharmaceuticals was 45.88. The lowest was 18.22. And the median was 23.19.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Bafna Pharmaceuticals E10 Related Terms


Bafna Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Bafna Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bafna Pharmaceuticals E10 Chart

Bafna Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 3.87 3.99

Bafna Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.87 4.09 4.12 3.96 3.99

NSE:BAFNAPH vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bafna Pharmaceuticals Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Bafna Pharmaceuticals's Shiller PE Ratio falls into.


NSE:BAFNAPH
59GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bafna Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.16/164.2724*164.2724
=1.160

Current CPI (Mar. 2026) = 164.2724.

Bafna Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201206 0.580 79.567 1.197
201209 1.110 82.244 2.217
201212 0.750 83.774 1.471
201303 -0.290 85.687 -0.556
201403 0.000 91.425 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201809 -0.800 115.142 -1.141
201812 0.040 115.142 0.057
201903 -5.952 118.202 -8.272
201906 -0.900 120.880 -1.223
201909 -0.250 123.175 -0.333
201912 -0.250 126.235 -0.325
202003 9.794 124.705 12.902
202006 7.660 127.000 9.908
202009 0.200 130.118 0.252
202012 0.380 130.889 0.477
202103 1.110 131.771 1.384
202106 0.880 134.084 1.078
202109 0.950 135.847 1.149
202112 0.720 138.161 0.856
202203 -0.345 138.822 -0.408
202206 0.580 142.347 0.669
202209 0.680 144.661 0.772
202212 1.260 145.763 1.420
202303 2.280 146.865 2.550
202306 2.680 150.280 2.930
202309 1.050 151.492 1.139
202312 -1.240 152.924 -1.332
202403 0.620 153.035 0.666
202406 -0.310 155.789 -0.327
202409 1.110 157.882 1.155
202412 0.400 158.323 0.415
202503 0.550 157.552 0.573
202506 1.430 159.755 1.470
202509 1.320 162.289 1.336
202512 0.780 163.281 0.785
202603 1.160 164.272 1.160

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹3.99 mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a E10 of ₹3.99 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Bafna Pharmaceuticals and its competitors.
Is Bafna Pharmaceuticals' E10 too high?
Bafna Pharmaceuticals' current E10 is ₹3.99. Overall, Bafna Pharmaceuticals has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' E10 compare to ZTS?
Bafna Pharmaceuticals' E10 of ₹3.99 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Bafna Pharmaceuticals and its competitors. Bafna Pharmaceuticals's current E10 is ₹3.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹90.56, compared to a current price of ₹194.68 — trading 115% above its estimated fair value. The current E10 is ₹3.99. Bafna Pharmaceuticals' overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current E10 is ₹3.99 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹194.68 is trading 115% above its estimated GF Value™ of ₹90.56. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • E10: ₹3.99
  • GF Value™: ₹90.56 vs. price of ₹194.68 (115% above fair value)
  • GF Score™: 59/100 with 5 warning signs

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
59GF Score

Get the complete analysis for NSE:BAFNAPH

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹194.68
Price
₹90.56
GF Value